New stent design for use in small coronary arteries during percutaneous coronary intervention

Juan F Granada1, Barbara A Huibregtse2, Keith D Dawkins21The Jack H Skirball Center for Cardiovascular Research, Cardiovascular Research Foundation, Columbia University Medical Center, New York, NY, USA; 2Boston Scientific Corporation, Natick, MA, USAAbstract: Patients with diabetes mellitus, of fem...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Juan F Granada, Barbara A Huibregtse, Keith D Dawkins
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Medical technology R855-855.5
Acceso en línea:	https://doaj.org/article/3f1366fe0f02431cadeb4d90e5a2eca5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3f1366fe0f02431cadeb4d90e5a2eca5
record_format	dspace
spelling	oai:doaj.org-article:3f1366fe0f02431cadeb4d90e5a2eca52021-12-02T05:03:43ZNew stent design for use in small coronary arteries during percutaneous coronary intervention1179-1470https://doaj.org/article/3f1366fe0f02431cadeb4d90e5a2eca52010-10-01T00:00:00Zhttp://www.dovepress.com/new-stent-design-for-use-in-small-coronary-arteries-during-percutaneou-a5523https://doaj.org/toc/1179-1470Juan F Granada1, Barbara A Huibregtse2, Keith D Dawkins21The Jack H Skirball Center for Cardiovascular Research, Cardiovascular Research Foundation, Columbia University Medical Center, New York, NY, USA; 2Boston Scientific Corporation, Natick, MA, USAAbstract: Patients with diabetes mellitus, of female gender, increased age, and/or with peripheral vascular disease often develop coronary stenoses in small caliber vessels. This review describes treatment of these lesions with the paclitaxel-eluting 2.25 mm TAXUS&reg; Libert&eacute;&reg; Atom&trade; stent. Given the same stent composition, polymer, antirestenotic drug (paclitaxel), and release kinetics as the first-generation 2.25 mm TAXUS&reg; Express&reg; Atom&trade; stent, the second-generation TAXUS Libert&eacute; Atom stent incorporates improved stent design characteristics, including thinner struts (0.0038 versus 0.0052 inches), intended to increase conformability and deliverability. In a porcine noninjured coronary artery model, TAXUS Libert&eacute; Atom stent implantation in small vessels demonstrated complete strut tissue coverage compared with the bare metal stent control, suggesting a similar degree of tissue healing between the groups at 30, 90, and 180 days. The prospective, single-armed TAXUS ATLAS Small Vessel trial demonstrated improved instent late loss (0.28 &plusmn; 0.45 versus 0.84 &plusmn; 0.57 mm, P &lt; 0.001), instent binary restenosis (13.0% versus 38.1%, P &lt; 0.001), and target lesion revascularization (5.8% versus 17.6%, P &lt; 0.001) at nine months with the TAXUS Libert&eacute; Atom stent as compared with the bare metal Express stent control, with similar safety measures between the two groups. The TAXUS Libert&eacute; Atom also significantly reduced nine-month angiographic rates of both instent late loss (0.28 &plusmn; 0.45 versus 0.44 &plusmn; 0.61 mm, P = 0.03) and instent binary restenosis (13.0% versus 25.9%, P = 0.02) when compared with the 2.25 mm TAXUS Express Atom control. The observed reduction in target lesion revascularization with the TAXUS Libert&eacute; Atom compared with the TAXUS Express Atom at nine months (5.8% versus 13.7%, P = 0.02) was sustained through three years (10.0% versus 22.1%, P = 0.008) with similar, stable safety outcomes between the groups. In conclusion, these data confirm the safety and favorable performance of the TAXUS Libert&eacute; Atom stent in the treatment of small coronary vessels.Keywords: small vessel, paclitaxel, stent Juan F GranadaBarbara A HuibregtseKeith D DawkinsDove Medical PressarticleMedical technologyR855-855.5ENMedical Devices: Evidence and Research, Vol 2010, Iss default, Pp 57-66 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medical technology R855-855.5
spellingShingle	Medical technology R855-855.5 Juan F Granada Barbara A Huibregtse Keith D Dawkins New stent design for use in small coronary arteries during percutaneous coronary intervention
description	Juan F Granada1, Barbara A Huibregtse2, Keith D Dawkins21The Jack H Skirball Center for Cardiovascular Research, Cardiovascular Research Foundation, Columbia University Medical Center, New York, NY, USA; 2Boston Scientific Corporation, Natick, MA, USAAbstract: Patients with diabetes mellitus, of female gender, increased age, and/or with peripheral vascular disease often develop coronary stenoses in small caliber vessels. This review describes treatment of these lesions with the paclitaxel-eluting 2.25 mm TAXUS&reg; Libert&eacute;&reg; Atom&trade; stent. Given the same stent composition, polymer, antirestenotic drug (paclitaxel), and release kinetics as the first-generation 2.25 mm TAXUS&reg; Express&reg; Atom&trade; stent, the second-generation TAXUS Libert&eacute; Atom stent incorporates improved stent design characteristics, including thinner struts (0.0038 versus 0.0052 inches), intended to increase conformability and deliverability. In a porcine noninjured coronary artery model, TAXUS Libert&eacute; Atom stent implantation in small vessels demonstrated complete strut tissue coverage compared with the bare metal stent control, suggesting a similar degree of tissue healing between the groups at 30, 90, and 180 days. The prospective, single-armed TAXUS ATLAS Small Vessel trial demonstrated improved instent late loss (0.28 &plusmn; 0.45 versus 0.84 &plusmn; 0.57 mm, P &lt; 0.001), instent binary restenosis (13.0% versus 38.1%, P &lt; 0.001), and target lesion revascularization (5.8% versus 17.6%, P &lt; 0.001) at nine months with the TAXUS Libert&eacute; Atom stent as compared with the bare metal Express stent control, with similar safety measures between the two groups. The TAXUS Libert&eacute; Atom also significantly reduced nine-month angiographic rates of both instent late loss (0.28 &plusmn; 0.45 versus 0.44 &plusmn; 0.61 mm, P = 0.03) and instent binary restenosis (13.0% versus 25.9%, P = 0.02) when compared with the 2.25 mm TAXUS Express Atom control. The observed reduction in target lesion revascularization with the TAXUS Libert&eacute; Atom compared with the TAXUS Express Atom at nine months (5.8% versus 13.7%, P = 0.02) was sustained through three years (10.0% versus 22.1%, P = 0.008) with similar, stable safety outcomes between the groups. In conclusion, these data confirm the safety and favorable performance of the TAXUS Libert&eacute; Atom stent in the treatment of small coronary vessels.Keywords: small vessel, paclitaxel, stent
format	article
author	Juan F Granada Barbara A Huibregtse Keith D Dawkins
author_facet	Juan F Granada Barbara A Huibregtse Keith D Dawkins
author_sort	Juan F Granada
title	New stent design for use in small coronary arteries during percutaneous coronary intervention
title_short	New stent design for use in small coronary arteries during percutaneous coronary intervention
title_full	New stent design for use in small coronary arteries during percutaneous coronary intervention
title_fullStr	New stent design for use in small coronary arteries during percutaneous coronary intervention
title_full_unstemmed	New stent design for use in small coronary arteries during percutaneous coronary intervention
title_sort	new stent design for use in small coronary arteries during percutaneous coronary intervention
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/3f1366fe0f02431cadeb4d90e5a2eca5
work_keys_str_mv	AT juanfgranada newstentdesignforuseinsmallcoronaryarteriesduringpercutaneouscoronaryintervention AT barbaraahuibregtse newstentdesignforuseinsmallcoronaryarteriesduringpercutaneouscoronaryintervention AT keithddawkins newstentdesignforuseinsmallcoronaryarteriesduringpercutaneouscoronaryintervention
_version_	1718400644490985472

New stent design for use in small coronary arteries during percutaneous coronary intervention

Ejemplares similares